Sailaja Kamaraju
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sailaja Kamaraju has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
Melinda Stolley
Med Coll Wisconsin, Dept Med, 8800 W Doyne Ave, Milwaukee, WI 53226 USA
5 shared publicationsAnjishnu Banerjee
4 shared publications- Hallgeir Rui
Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania
3 shared publications Joan Neuner
Center for Patient Care and Outcomes Research, Medical College of Wisconsin, Milwaukee, Wisconsin
3 shared publications- Julie M. Jorns
Medical College of Wisconsin
3 shared publications Kate Krause
Massachusettes General Hospital, Boston, MA, USA
3 shared publications
Latest Publications
- 29 June 2026
- Published by SAGE Publications in Journal of Prevention and Health Promotion
- Vol. 7 (4) , 572-588
Pathways to Cancer Prevention and Screening: Developing a Training to Educate the Community Health Worker Workforce
Diagnoses of cancer at later stages contribute to racial/ethnic disparities in cancer survival, with African Americans/Blacks and sometimes Hispanics experiencing poorer 5-year survival rates for breast, cervical, colorectal, lung, and prostate cancers. Interventions that promote early detection and cancer prevention are critically needed to reduce racial/ethnic disparities in cancer survival. The purpose of this study was to develop the Pathways to Cancer Prevention and Screening training program to educate community health workers (CHWs) on cancer prevention and screening guidelines; and cancer screening referrals for breast, cervical, colorectal, lung, and prostate cancers. We examined pre- and post-training changes among CHWs in (a) cancer prevention and knowledge overall and by sub-category: cancer knowledge, screening, and preventive lifestyles; (b) cancer fear and fatalism; and (c) comfort discussing screening guidelines. In an urban area using a quasi-experimental design, we recruited 47 CHWs, with 44 who completed pre- and post-assessments. Statistically significant changes that suggest improvement in mean cancer knowledge prevention scores overall and by sub-categories: cancer knowledge, cancer screening, and preventive lifestyles. Improvements in cancer fear and fatalism were marginally significant, and comfort in discussing cancer screening guidelines significantly improved from pre- to post-assessment. Pathways to Cancer Prevention and Screening is a feasible way to improve knowledge of cancers, and screening guidelines for breast, cervical, prostate, lung, and colorectal cancers. Investing in CHW workforce development can improve the quality of one-on-one education to clients with increased risk for five of the most prevalent forms of cancer.
- 29 June 2026
- Published by SAGE Publications in Journal of Prevention and Health Promotion
- Vol. 7 (4) , 572-588
Pathways to Cancer Prevention and Screening: Developing a Training to Educate the Community Health Worker Workforce
Diagnoses of cancer at later stages contribute to racial/ethnic disparities in cancer survival, with African Americans/Blacks and sometimes Hispanics experiencing poorer 5-year survival rates for breast, cervical, colorectal, lung, and prostate cancers. Interventions that promote early detection and cancer prevention are critically needed to reduce racial/ethnic disparities in cancer survival. The purpose of this study was to develop the Pathways to Cancer Prevention and Screening training program to educate community health workers (CHWs) on cancer prevention and screening guidelines; and cancer screening referrals for breast, cervical, colorectal, lung, and prostate cancers. We examined pre- and post-training changes among CHWs in (a) cancer prevention and knowledge overall and by sub-category: cancer knowledge, screening, and preventive lifestyles; (b) cancer fear and fatalism; and (c) comfort discussing screening guidelines. In an urban area using a quasi-experimental design, we recruited 47 CHWs, with 44 who completed pre- and post-assessments. Statistically significant changes that suggest improvement in mean cancer knowledge prevention scores overall and by sub-categories: cancer knowledge, cancer screening, and preventive lifestyles. Improvements in cancer fear and fatalism were marginally significant, and comfort in discussing cancer screening guidelines significantly improved from pre- to post-assessment. Pathways to Cancer Prevention and Screening is a feasible way to improve knowledge of cancers, and screening guidelines for breast, cervical, prostate, lung, and colorectal cancers. Investing in CHW workforce development can improve the quality of one-on-one education to clients with increased risk for five of the most prevalent forms of cancer.
- 10 December 2024
- Published by Elsevier in Clinical Breast Cancer
- Vol. 25 (3) , 251-260
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer
- 10 December 2024
- Published by Elsevier in Clinical Breast Cancer
- Vol. 25 (3) , 251-260
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer
- 26 November 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 209 (3) , 541-552
The association of distress and depression screening measures and other electronic health record information with adjuvant endocrine therapy persistence
Purpose Few risk factors for early adjuvant endocrine discontinuation have been identified, but clinical trials suggest pre-AET symptom burden might be important. We sought to assess this in an academic practice. Methods We examined baseline and up to five years of follow-up information for postmenopausal women with stage I–III hormone-receptor positive breast cancer 2014–2019 receiving oncologist prescriptions for AET. The Distress Thermometer (DT) and its problem list, the Patient Health Questionnaire 2/9 (PHQ 2/9), cancer extent of disease and treatments, comorbidities, sociodemographics, and pharmacy prescription fill dates were abstracted from the cancer registry and electronic health record (EHR). The association of these variables with early AET prescription fill discontinuation (prior to 5 years) was examined using survival analysis and Bayesian machine learning, with censoring for recurrence, death, or provider change. Results Among the cohort of 961 women (mean 68.8 years, SD 2.88), 91.6% were white, 74.6% had Stage I disease, and 45.0% a pre-AET DT showing high distress (> 3). The median follow-up time was 820 (25, 75% 448,1282) days, and 29.6% discontinued early. Neither the DT score nor the PHQ 2/9 was associated with nonadherence, although three physical problems were modestly associated. Over 25% of women who stopped filling prescriptions did not have their prescriptions discontinued in the EHR. Conclusions Several commonly available baseline EHR variables were not associated with early discontinuation, although some symptoms may have modest effects. Many women who discontinued still had EHR prescriptions, suggesting that physicians could use prescription fill information to intervene earlier.
- 26 November 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 209 (3) , 541-552
The association of distress and depression screening measures and other electronic health record information with adjuvant endocrine therapy persistence
Purpose Few risk factors for early adjuvant endocrine discontinuation have been identified, but clinical trials suggest pre-AET symptom burden might be important. We sought to assess this in an academic practice. Methods We examined baseline and up to five years of follow-up information for postmenopausal women with stage I–III hormone-receptor positive breast cancer 2014–2019 receiving oncologist prescriptions for AET. The Distress Thermometer (DT) and its problem list, the Patient Health Questionnaire 2/9 (PHQ 2/9), cancer extent of disease and treatments, comorbidities, sociodemographics, and pharmacy prescription fill dates were abstracted from the cancer registry and electronic health record (EHR). The association of these variables with early AET prescription fill discontinuation (prior to 5 years) was examined using survival analysis and Bayesian machine learning, with censoring for recurrence, death, or provider change. Results Among the cohort of 961 women (mean 68.8 years, SD 2.88), 91.6% were white, 74.6% had Stage I disease, and 45.0% a pre-AET DT showing high distress (> 3). The median follow-up time was 820 (25, 75% 448,1282) days, and 29.6% discontinued early. Neither the DT score nor the PHQ 2/9 was associated with nonadherence, although three physical problems were modestly associated. Over 25% of women who stopped filling prescriptions did not have their prescriptions discontinued in the EHR. Conclusions Several commonly available baseline EHR variables were not associated with early discontinuation, although some symptoms may have modest effects. Many women who discontinued still had EHR prescriptions, suggesting that physicians could use prescription fill information to intervene earlier.
- Open Access
- 23 October 2024
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 31 (12) , 2940-2951
Equitable community-based participatory research engagement with communities of color drives All of Us Wisconsin genomic research priorities
The NIH All of Us Research Program aims to advance personalized medicine by not only linking patient records, surveys, and genomic data but also engaging with participants, particularly from groups traditionally underrepresented in biomedical research (UBR). This study details how the dialogue between scientists and community members, including many from communities of color, shaped local research priorities. We recruited area quantitative, basic, and clinical scientists as well as community members from our Community and Participant Advisory Boards with a predetermined interest in All of Us research as members of a Special Interest Group (SIG). An expert community engagement scientist facilitated 6 SIG meetings over the year, explicitly fostering openness and flexibility during conversations. We qualitatively analyzed discussions using a social movement framework tailored for community-based participatory research (CBPR) mobilization. The SIG evolved through CBPR stages of emergence, coalescence, momentum, and maintenance/integration. Researchers prioritized community needs above personal academic interests while community members kept discussions focused on tangible return of value to communities. One key outcome includes SIG-driven shifts in programmatic and research priorities of the All of Us Research Program in Southeastern Wisconsin. One major challenge was building equitable conversations that balanced scientific rigor and community understanding. Our approach allowed for a rich dialogue to emerge. Points of connection and disconnection between community members and scientists offered important guidance for emerging areas of genomic inquiry. Our study presents a robust foundation for future efforts to engage diverse communities in CBPR, particularly on healthcare concerns affecting UBR communities.
- 23 October 2024
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 31 (12) , 2940-2951
Open AccessEquitable community-based participatory research engagement with communities of color drives All of Us Wisconsin genomic research priorities
The NIH All of Us Research Program aims to advance personalized medicine by not only linking patient records, surveys, and genomic data but also engaging with participants, particularly from groups traditionally underrepresented in biomedical research (UBR). This study details how the dialogue between scientists and community members, including many from communities of color, shaped local research priorities. We recruited area quantitative, basic, and clinical scientists as well as community members from our Community and Participant Advisory Boards with a predetermined interest in All of Us research as members of a Special Interest Group (SIG). An expert community engagement scientist facilitated 6 SIG meetings over the year, explicitly fostering openness and flexibility during conversations. We qualitatively analyzed discussions using a social movement framework tailored for community-based participatory research (CBPR) mobilization. The SIG evolved through CBPR stages of emergence, coalescence, momentum, and maintenance/integration. Researchers prioritized community needs above personal academic interests while community members kept discussions focused on tangible return of value to communities. One key outcome includes SIG-driven shifts in programmatic and research priorities of the All of Us Research Program in Southeastern Wisconsin. One major challenge was building equitable conversations that balanced scientific rigor and community understanding. Our approach allowed for a rich dialogue to emerge. Points of connection and disconnection between community members and scientists offered important guidance for emerging areas of genomic inquiry. Our study presents a robust foundation for future efforts to engage diverse communities in CBPR, particularly on healthcare concerns affecting UBR communities.
- 27 May 2024
- Published by Springer Nature in Current Oncology Reports
- Vol. 26 (8) , 855-864
An Annual Symposium on Disparities in Milwaukee, WI, with a 2023 Focus on Older Adults with Cancer
Purpose of ReviewCancer-related inequities are prevalent in Wisconsin, with lower survival rates for breast, colorectal, and lung cancer patients from marginalized communities. This manuscript describes the ongoing efforts at the Medical College of Wisconsin and potential pathways of community engagement to promote education and awareness in reducing inequities in cancer care.Recent FindingsWhile some cancer inequities are related to aggressive disease biology, health-related social risks may be addressed through community-academic partnerships via an open dialogue between the community members and academic faculty. To develop potential pathways of community-academic partnerships, an annual Cancer Disparities Symposium concept evolved as a pragmatic and sustainable model in an interactive learning environment.SummaryIn this manuscript, we describe the programmatic development and execution of the annual Cancer Disparities Symposium, followed by highlights from this year's meeting focused on geriatric oncology as discussed by the speakers.
- 27 May 2024
- Published by Springer Nature in Current Oncology Reports
- Vol. 26 (8) , 855-864
An Annual Symposium on Disparities in Milwaukee, WI, with a 2023 Focus on Older Adults with Cancer
Purpose of ReviewCancer-related inequities are prevalent in Wisconsin, with lower survival rates for breast, colorectal, and lung cancer patients from marginalized communities. This manuscript describes the ongoing efforts at the Medical College of Wisconsin and potential pathways of community engagement to promote education and awareness in reducing inequities in cancer care.Recent FindingsWhile some cancer inequities are related to aggressive disease biology, health-related social risks may be addressed through community-academic partnerships via an open dialogue between the community members and academic faculty. To develop potential pathways of community-academic partnerships, an annual Cancer Disparities Symposium concept evolved as a pragmatic and sustainable model in an interactive learning environment.SummaryIn this manuscript, we describe the programmatic development and execution of the annual Cancer Disparities Symposium, followed by highlights from this year's meeting focused on geriatric oncology as discussed by the speakers.
- 1 May 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (5) , 688-698
Challenges and Solutions to Support Oncology Professionals Serving Underserved Populations With Cancer in the United States: Results From the ASCO Serving the Underserved Task Force
PURPOSE: Little data exist regarding approaches to support oncology professionals who deliver cancer care for underserved populations. In response, ASCO developed the Serving the Underserved Task Force to learn from and support oncology professionals serving underserved populations. METHODS: The Task Force developed a 28-question survey to assess oncology professionals' experiences and strategies to support their work caring for underserved populations. The survey was deployed via an online link to 600 oncology professionals and assessed respondent and patient demographic characteristics, clinic-based processes to coordinate health-related social services, and strategies for professional society support and engagement. We used chi-square tests to evaluate whether there were associations between percent full-time equivalent (FTE) effort serving underserved populations (<50% FTE v ≥50% FTE) with responses. RESULTS: Of 462 respondents who completed the survey (77% response rate), 79 (17.1%) were Asian; 30 (6.5%) Black; 43 (9.3%) Hispanic or Latino/Latina; and 277 (60%) White. The majority (n = 366, 79.2%) had a medical doctor degree (MD). A total of 174 (37.7%) had <25% FTE, 151 (32.7%) had 25%-50% FTE, and 121 (26.2%) had ≥50% FTE effort serving underserved populations. Most best guessed patients' sociodemographic characteristics (n = 388; 84%), while 42 (9.2%) used data collected by the clinic. Social workers coordinated most health-related social services. However, in clinical settings with high proportions of underserved patients, there was greater reliance on nonclinical personnel, such as navigators (odds ratio [OR], 2.15 [95% CI, 1.07 to 4.33]) or no individual (OR, 2.55 [95% CI, 1.14 to 5.72]) for addressing mental health needs and greater reliance on physicians or advance practice practitioners (OR, 2.54 [95% CI, 1.11 to 5.81]) or no individual (OR, 1.91 [95% CI, 1.09 to 3.35]) for addressing childcare or eldercare needs compared with social workers. Prioritization of solutions, which did not differ by FTE effort serving underserved populations, included a return-on-investment model to support personnel, integrated health-related social needs screening, and collaboration with the professional society on advocacy and policy. CONCLUSION: The findings highlight crucial strategies that professional societies can implement to support oncology clinicians serving underserved populations with cancer.
- 1 May 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (5) , 688-698
Challenges and Solutions to Support Oncology Professionals Serving Underserved Populations With Cancer in the United States: Results From the ASCO Serving the Underserved Task Force
PURPOSE: Little data exist regarding approaches to support oncology professionals who deliver cancer care for underserved populations. In response, ASCO developed the Serving the Underserved Task Force to learn from and support oncology professionals serving underserved populations. METHODS: The Task Force developed a 28-question survey to assess oncology professionals' experiences and strategies to support their work caring for underserved populations. The survey was deployed via an online link to 600 oncology professionals and assessed respondent and patient demographic characteristics, clinic-based processes to coordinate health-related social services, and strategies for professional society support and engagement. We used chi-square tests to evaluate whether there were associations between percent full-time equivalent (FTE) effort serving underserved populations (<50% FTE v ≥50% FTE) with responses. RESULTS: Of 462 respondents who completed the survey (77% response rate), 79 (17.1%) were Asian; 30 (6.5%) Black; 43 (9.3%) Hispanic or Latino/Latina; and 277 (60%) White. The majority (n = 366, 79.2%) had a medical doctor degree (MD). A total of 174 (37.7%) had <25% FTE, 151 (32.7%) had 25%-50% FTE, and 121 (26.2%) had ≥50% FTE effort serving underserved populations. Most best guessed patients' sociodemographic characteristics (n = 388; 84%), while 42 (9.2%) used data collected by the clinic. Social workers coordinated most health-related social services. However, in clinical settings with high proportions of underserved patients, there was greater reliance on nonclinical personnel, such as navigators (odds ratio [OR], 2.15 [95% CI, 1.07 to 4.33]) or no individual (OR, 2.55 [95% CI, 1.14 to 5.72]) for addressing mental health needs and greater reliance on physicians or advance practice practitioners (OR, 2.54 [95% CI, 1.11 to 5.81]) or no individual (OR, 1.91 [95% CI, 1.09 to 3.35]) for addressing childcare or eldercare needs compared with social workers. Prioritization of solutions, which did not differ by FTE effort serving underserved populations, included a return-on-investment model to support personnel, integrated health-related social needs screening, and collaboration with the professional society on advocacy and policy. CONCLUSION: The findings highlight crucial strategies that professional societies can implement to support oncology clinicians serving underserved populations with cancer.
- Open Access
- 29 April 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (5) , 478
Divergent Cellular Expression Patterns of PD-L1 and PD-L2 Proteins in Breast Cancer
PD-L1 immunohistochemistry (IHC) has become an established method for predicting cancer response to targeted anti-PD1 immunotherapies, including breast cancer (BC). The alternative PD-1 ligand, PD-L2, remains understudied but may be a complementary predictive marker. Prospective analysis of 32 breast cancers revealed divergent expression patterns of PD-L1 and PD-L2. PD-L1-positivity was higher in immune cells than in cancer cells (median = 5.0% vs. 0.0%; p = 0.001), whereas PD-L2-positivity was higher in cancer cells than immune cells (median = 30% vs. 5.0%; p = 0.001). Percent positivity of PD-L1 and PD-L2 were not correlated, neither in cancer cells nor immune cells. Based on a cut-point of ≥1% positivity, ER+ tumors (n = 23) were frequently PD-L2-positive (73.9%), whereas only 40.9% were PD-L1-positive. These data suggest differential control of cellular PD-L1 and PD-L2 expression in BC and a potential role for PD-L2 IHC as a complementary marker to PD-L1 to improve selection of aggressive ER+ BC that may benefit from anti-PD-1 therapy.
- 29 April 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (5) , 478
Open AccessDivergent Cellular Expression Patterns of PD-L1 and PD-L2 Proteins in Breast Cancer
PD-L1 immunohistochemistry (IHC) has become an established method for predicting cancer response to targeted anti-PD1 immunotherapies, including breast cancer (BC). The alternative PD-1 ligand, PD-L2, remains understudied but may be a complementary predictive marker. Prospective analysis of 32 breast cancers revealed divergent expression patterns of PD-L1 and PD-L2. PD-L1-positivity was higher in immune cells than in cancer cells (median = 5.0% vs. 0.0%; p = 0.001), whereas PD-L2-positivity was higher in cancer cells than immune cells (median = 30% vs. 5.0%; p = 0.001). Percent positivity of PD-L1 and PD-L2 were not correlated, neither in cancer cells nor immune cells. Based on a cut-point of ≥1% positivity, ER+ tumors (n = 23) were frequently PD-L2-positive (73.9%), whereas only 40.9% were PD-L1-positive. These data suggest differential control of cellular PD-L1 and PD-L2 expression in BC and a potential role for PD-L2 IHC as a complementary marker to PD-L1 to improve selection of aggressive ER+ BC that may benefit from anti-PD-1 therapy.
- 2 April 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (4) , 1-9
Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women
Purpose Oral adjuvant endocrine therapy (AET) is an effective treatment for hormone receptor positive breast cancer to decrease recurrence and mortality, but adherence is poor. This study explored post-menopausal women’s experiences with AET, with a particular focus on adherence to AET as well as distress and symptoms experienced prior to and during AET treatment. Methods Participants were recruited from a hospital registry, stratified by adherence to/discontinuation of AET. Telephone interviews followed a semi-structured interview guide and were recorded and transcribed verbatim. Transcripts were systematically coded using team-based coding, with analysis of themes using a grounded theory approach. Results Thirty-three participants were interviewed; ages ranged from 57 to 86 years. Participants included 10 discontinued patients and 23 patients who completed their AET course or were adherent to AET at the time of interviewing. Both adherent and discontinued patients reported symptoms throughout their AET treatment course, and both attributed symptoms to factors other than AET (e.g., older age and pre-existing comorbidities). However, discontinued patients were more likely to attribute symptoms to AET and to describe difficulty managing their symptoms, with some directly citing symptoms as the reason for discontinuing AET therapy. Conversely, adherent patients were more likely to describe the necessity of taking AET, despite symptoms. Conclusions AET adherence was associated with beliefs about AET, symptom attribution, and symptom management. Routine symptom monitoring during AET and addressing both symptoms and patients’ understanding of their symptoms may promote adherence to AET.
- 2 April 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (4) , 1-9
Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women
Purpose Oral adjuvant endocrine therapy (AET) is an effective treatment for hormone receptor positive breast cancer to decrease recurrence and mortality, but adherence is poor. This study explored post-menopausal women’s experiences with AET, with a particular focus on adherence to AET as well as distress and symptoms experienced prior to and during AET treatment. Methods Participants were recruited from a hospital registry, stratified by adherence to/discontinuation of AET. Telephone interviews followed a semi-structured interview guide and were recorded and transcribed verbatim. Transcripts were systematically coded using team-based coding, with analysis of themes using a grounded theory approach. Results Thirty-three participants were interviewed; ages ranged from 57 to 86 years. Participants included 10 discontinued patients and 23 patients who completed their AET course or were adherent to AET at the time of interviewing. Both adherent and discontinued patients reported symptoms throughout their AET treatment course, and both attributed symptoms to factors other than AET (e.g., older age and pre-existing comorbidities). However, discontinued patients were more likely to attribute symptoms to AET and to describe difficulty managing their symptoms, with some directly citing symptoms as the reason for discontinuing AET therapy. Conversely, adherent patients were more likely to describe the necessity of taking AET, despite symptoms. Conclusions AET adherence was associated with beliefs about AET, symptom attribution, and symptom management. Routine symptom monitoring during AET and addressing both symptoms and patients’ understanding of their symptoms may promote adherence to AET.
- Open Access
- 1 April 2024
- Published by AME Publishing Company in Annals of Cancer Epidemiology
- Vol. 8, 2
Addressing social determinants of health for oncology patients: can we reduce hospital readmissions?
Background: Cancer patients with health-related social risks may be at higher risk for readmissions. This study assesses the impact of the recently integrated social determinants of health (SDOH) survey on inpatient oncology 30-day hospital readmissions. Methods: We evaluated readmissions data from inpatient oncology units from January 1, 2019–December 31, 2021 using our internal Electronic Medical Record (EMR), and Vizient Clinical Data Base linked to patients’ socioeconomic status (SES) data. Secondary analyses included patient demographics and others as main predictors of readmissions. Logistic regression models controlled for various patient demographic factors. We compared the readmission rate before and after the EMR integration of the SDOH survey. Results: A total of 1,853 solid tumor oncology patients were admitted during the study period, among which 751 admissions were before the SDOH survey, and 1,102 were after the survey. Although there were no significant differences in the 30-day readmissions before vs. after the EMR integration of the SDOH survey, there were significant subgroup differences. For example, in the readmission cohort, the following differences were observed: a higher proportion of patients were younger (25%, PConclusions: Our study results demonstrated no overall differences in the 30-day readmission rate before vs. after implementation of the SDOH survey, however, NHB patients and Medicaid users have a higher risk for readmission even with the examination of their barriers to SDOH at the time of admission. This study shows that additional factors such as disease complexity and comorbidities may impact hospital readmissions.
- 1 April 2024
- Published by AME Publishing Company in Annals of Cancer Epidemiology
- Vol. 8, 2
Open AccessAddressing social determinants of health for oncology patients: can we reduce hospital readmissions?
Background: Cancer patients with health-related social risks may be at higher risk for readmissions. This study assesses the impact of the recently integrated social determinants of health (SDOH) survey on inpatient oncology 30-day hospital readmissions. Methods: We evaluated readmissions data from inpatient oncology units from January 1, 2019–December 31, 2021 using our internal Electronic Medical Record (EMR), and Vizient Clinical Data Base linked to patients’ socioeconomic status (SES) data. Secondary analyses included patient demographics and others as main predictors of readmissions. Logistic regression models controlled for various patient demographic factors. We compared the readmission rate before and after the EMR integration of the SDOH survey. Results: A total of 1,853 solid tumor oncology patients were admitted during the study period, among which 751 admissions were before the SDOH survey, and 1,102 were after the survey. Although there were no significant differences in the 30-day readmissions before vs. after the EMR integration of the SDOH survey, there were significant subgroup differences. For example, in the readmission cohort, the following differences were observed: a higher proportion of patients were younger (25%, PConclusions: Our study results demonstrated no overall differences in the 30-day readmission rate before vs. after implementation of the SDOH survey, however, NHB patients and Medicaid users have a higher risk for readmission even with the examination of their barriers to SDOH at the time of admission. This study shows that additional factors such as disease complexity and comorbidities may impact hospital readmissions.
- 1 February 2024
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 124, 102695
Challenges to genetic testing for germline mutations associated with breast cancer among African Americans
- 1 February 2024
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 124, 102695
Challenges to genetic testing for germline mutations associated with breast cancer among African Americans